Sunday, March 07, 2021 7:45:35 PM
Just watching on "60 Minutes" about Fluvoximine Maleate pills used on people who got Covid. Those who took this pills recovered without going to the hospital. Interesting considering the pills was for Obsessive Compulsive Disorder.
Recent JAZZ News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:27:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:13:14 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:06:23 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:19:10 PM
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA • PR Newswire (US) • 04/27/2026 11:45:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:09:04 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) • PR Newswire (US) • 04/21/2026 08:05:00 PM
- Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/09/2026 11:45:00 AM
- Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference • PR Newswire (US) • 04/01/2026 08:15:00 PM
- American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education • PR Newswire (US) • 03/24/2026 05:49:00 PM
- Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 • PR Newswire (US) • 03/18/2026 11:44:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:27:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:25:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:21:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:15:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:10:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:07:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:26:33 PM
